These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28696366)

  • 41. MET targeted therapy for lung cancer: clinical development and future directions.
    Feng Y; Ma PC
    Lung Cancer (Auckl); 2012; 3():53-67. PubMed ID: 28210125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crizotinib and erlotinib inhibits growth of c-Met
    Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
    Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
    Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
    Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
    Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
    IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
    Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
    Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paeoniflorin Inhibits Hepatocyte Growth Factor- (HGF-) Induced Migration and Invasion and Actin Rearrangement via Suppression of c-Met-Mediated RhoA/ROCK Signaling in Glioblastoma.
    Yu G; Wang Z; Zeng S; Liu S; Zhu C; Xu R; Liu RE
    Biomed Res Int; 2019; 2019():9053295. PubMed ID: 30886866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.
    Wang H; Rao B; Lou J; Li J; Liu Z; Li A; Cui G; Ren Z; Yu Z
    Front Cell Dev Biol; 2020; 8():55. PubMed ID: 32117981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.
    Hara T; Kimura A; Miyazaki T; Tanaka H; Morimoto M; Nakai K; Soeda J
    Biochem Biophys Rep; 2020 Mar; 21():100726. PubMed ID: 32055714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
    Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
    Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
    Zhang Y; Jain RK; Zhu M
    Biomedicines; 2015 Mar; 3(1):149-181. PubMed ID: 28536405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. c-Met expression in renal cell carcinoma with bone metastases.
    Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
    J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.
    Dhruv HD; Roos A; Tomboc PJ; Tuncali S; Chavez A; Mathews I; Berens ME; Loftus JC; Tran NL
    J Neurooncol; 2016 Feb; 126(3):397-404. PubMed ID: 26559543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
    Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
    PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
    Huang X; Gan G; Wang X; Xu T; Xie W
    Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.